Navigation Links
Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
Date:10/31/2007

LAKE FOREST, Ill, Oct. 31 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global hospital products company, announced today that Thomas E. Werner, senior vice president, Finance, and chief financial officer, will make a formal presentation at the Credit Suisse Phoenix Health Care Conference on Tuesday, Nov. 13, 2007, in Phoenix.

The presentation will be accessible to all interested parties at noon Mountain Time on Tuesday, Nov. 13, 2007, through a live audiocast in the investor relations section of Hospira's Web site at http://www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the audiocast. The slides accompanying the presentation will be available on the Hospira Web site beginning at 11:45 a.m. Mountain Time. A replay will be available on the Hospira Web site approximately 24 hours after the live presentation until Nov. 27.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM) by developing, manufacturing and marketing products that help improve the productivity, safety and efficacy of patient care. In February 2007, Hospira acquired Mayne Pharma Limited to become the world leader in specialty generic injectable pharmaceuticals. With 70 years of service to the hospital industry, Hospira's portfolio includes one of the industry's broadest lines of generic acute-care and oncology injectables, which help address the high cost of proprietary pharmaceuticals; and integrated solutions for medication management and infusion therapy. Headquartered north of Chicago in Lake Forest, I
'/>"/>

SOURCE Hospira, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... A cleanroom manufacturing company has ...eanrooms. The feature is a utility panel which ca...nce the cleanroom appearance. , ...Gerbig Engineering, a designer, fabricator and ins...they are now offering a utility panel for integrat...
(Date:7/23/2008)...und,s Commitment to Meet the Financing Needs of Eu...and Institutions--, NEW YORK, July 24 /PRNewswire...n Macleod, Ph.D., has been promoted to Partner. Ba...s responsible for sourcing,evaluating and negotia...rtunities for the Paul Capital Healthcare funds., ...
(Date:7/23/2008)...M, N.C. A study out of Wake Forest University Bap...ctors are correctly identifying patients who are h...aven,t yet confirmed it. , The study used data f...ts with heart attack symptoms who were admitted to...g U.S. centers. , The findings were released to...
(Date:7/23/2008)...d Problem For 10+ Years Even Though Some Kilns Emi...n Cement Kilns in AL, CA, IA,IL, MD, MI, MT, NY, ...wire-USNewswire/ -- For more than a decade,after C...n from cement,kilns across the nation, the U.S. En...e action. Now, a new study from Earthjustice and t...
Breaking Medicine News(10 mins):Health News:Gerbig Engineering Announces Availability of Cleanroom Utility Panel 2Health News:Paul Capital Partners Promotes Ken Macleod To Partner 2Health News:Paul Capital Partners Promotes Ken Macleod To Partner 3Health News:Study shows emergency physicians have good first instincts in diagnosing heart attacks 2Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 2Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 3Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 4Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 5Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 6Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 7
... Health Organization estimates that 40 million peo.../of them in developing countries. In some African ...irus. Last year, an estimated 700,000 children cau...the risk is greatest, researchers have settled on ...
Cholesterol-lowering drug Found To greatly Reduce the risk of stroke and heart attack
...ncer survivors can now get up and get moving. Brea... older women, reported higher body esteem and bett...a new study. Researchers compared 40 women who sa...ary women, all early-stage breast cancer survivors...
... took the most antibiotics , or who took the drugs... // developing breast cancer over an average of ab...he drugs, the study showed. Also, since antibiotic...common infections caused by bacteria, some pneumon...
Other Medicine News:Health News:Drug to stop HIV spread to babies may Indirectly harm The Mother 2
(Date:7/23/2008)..., July 23 /- Sound Pharmaceuticals (S...ion with the FDA for the clinical,testing of a pro... of,chemotherapy induced hearing loss or ototoxici... will be tested in advanced stage lung cancer,and ...ased chemotherapy.,This marks the second developme...
(Date:7/23/2008)..., July 23 /- Dendreon Corpo...pects the Independent Data,Monitoring Committee (I...s,of overall survival relating to the Company,s Ph...inoma Treatment, also known as D9902B) clinical tr... Company,s investigational,active cellular immunot...
(Date:7/22/2008)...awards under Therapeutics Development Initiative b... to 23; next deadline January 20,2009, NEW YORK,... mission to,speed delivery of transformative treat...ael J. Fox Foundation for Parkinson,s Research has...stry research teams. The awards,were granted under...
(Date:7/22/2008)...frey Allan Will Stress the Importance to Patients ...Approval Pathway, RICHMOND, Va., July 22 /PRNewsw...developer of follow-on biologics and biopharmaceut... CEO of Insmed, will present at a,Congressional br...ignificant need for establishing an approval pathw...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp of Washington 1755 1Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp of Washington 1755 2Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp of Washington 1755 3Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp of Washington 1755 4Interferon does not slow or stop hepatitis C from worsening study finds 5962 1Interferon does not slow or stop hepatitis C from worsening study finds 5962 2UC San Diego Engineering Honor Society wins most outstanding chapter award 1161 1UC San Diego Engineering Honor Society wins most outstanding chapter award 1161 2Pill Poses Little Cervical Cancer Risk 5956 1Pill Poses Little Cervical Cancer Risk 5956 2Pill Poses Little Cervical Cancer Risk 5956 3
...rocleix System has added a significant layer of a ...nnovative technologies developed by Gen-Probe incl...plification technique called Transcription-Mediate...ay can simultaneously detect the presence of HIV-1...
...Antibody Test (Reveal Test) is MedMiras flagship r...an serum or plasma against HIV-1 that are produced...eal Test is based on MedMiras proprietary flow-thr...ngle-use test cartridge containing an immunoreacti...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple
X-Hair Trephines
Medicine Products: